Quality issue at Baltimore vaccine plant delays some of Johnson & Johnson’s vaccine
Drugmaker Johnson & Johnson said Wednesday it had found a quality problem at a Baltimore plant helping manufacture its single-dose coronavirus vaccine under contract. The New York Times reported Wednesday. that workers at Emergent BioSolutions, the Baltimore plant that has been making Johnson & Johnson’s Covid-19 vaccine, accidentally mixed up some of the ingredients, ruining
Continue Reading